Scienture Holdings (SCNX) AI Stock Analysis

• Market Cap: $15.62M
• Dividend Yield: N/A
• Average Volume (3M): 4.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.63
• Revenue Growth: -73.18%
• EPS Growth: 92.38%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -11.60
• Shares Outstanding: 40,630,814
• 10 Day Avg. Volume: 11,411,402
• 30 Day Avg. Volume: 4,082,790
• PEG Ratio: -0.02
• Price to Book (P/B): 0.26
• Price to Sales (P/S): 149.45
• P/FCF Ratio: -1.43
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 12.68
• Enterprise Value/Gross Profit: 14.73
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $1.50
• Price Target Upside: 172.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.44 ▼(-19.82% Downside)
• Action: Upgraded Date: 01/13/26
• Date: Action: Upgraded 01/13/26

The score is held down primarily by severe, persistent losses and ongoing cash burn, which create high execution and funding risk despite the recent revenue rebound and strong gross margin. Technicals also remain weak with bearish longer-term trends, and a Nasdaq bid-price compliance notice adds further downside risk. Valuation provides limited support because earnings are negative and no dividend yield is provided.

Positive Factors

High gross margin and TTM revenue rebound

Very high gross margins combined with a sharp TTM revenue rebound indicate strong unit economics on the company's offerings. If sustained, these margins provide structural leverage as revenue scales, improving long-run operating leverage and making profitable growth more achievable once fixed costs are controlled.

Diversified, recurring revenue channels

A mix of subscription software licensing, consulting fees, milestone payments and partnerships creates diversified revenue streams and recurring elements. This business model reduces single-customer concentration risk and supports steadier revenue visibility and customer stickiness over a multi-month horizon.

Expanded equity distribution agreement

Raising the capacity under the equity distribution agreement materially increases near-term financing optionality. This structural enhancement to capital access reduces short-term funding stress and gives management more flexibility to fund R&D, operations, or partnerships without immediate reliance on bank debt.

Negative Factors

Persistent negative operating and free cash flow

Sustained negative operating and free cash flow signals the business is not funding operations internally, forcing reliance on external capital. Over months this raises execution and dilution risk, constrains reinvestment, and limits runway for commercial expansion absent reliable financing sources.

Large operating losses relative to sales

Very large operating losses versus a small revenue base undermine the trajectory to sustainable profitability. This structural earnings gap reduces financial resilience, weakens return on invested capital, and increases the risk that future growth will require ongoing subsidization by new capital.

Nasdaq minimum bid price non-compliance risk

A Nasdaq bid-price non-compliance notice is a structural governance and liquidity risk: potential delisting or remediation actions can reduce investor access and liquidity, distract management, and make future capital raises more difficult, affecting strategic execution over months.

Scienture Holdings Business Overview & Revenue Model

Company Description

TRxADE HEALTH, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, hospitals, clinics and independent pharmacies. TRxADE HEALTH, Inc. is headquartered in Tampa, Florida.

How the Company Makes Money

Scienture Holdings generates revenue through multiple channels, including software licensing fees for its proprietary analytics platforms, consulting services for clinical trial optimization, and partnerships with pharmaceutical companies for collaborative research projects. Key revenue streams include subscription-based models for software products, one-time fees for consulting services, and milestone payments from strategic partnerships. The company also benefits from grants and funding related to research initiatives, which contribute to its overall earnings.

Scienture Holdings Financial Statement Overview

Summary

Despite a sharp TTM revenue rebound and very high gross margin, the financial profile is dominated by extremely large operating losses and substantial net losses. Cash flow is persistently negative with ongoing free cash flow burn, increasing funding risk. The balance sheet shows currently modest leverage, but historical capital structure instability and negative ROE keep the overall financial score low.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply versus the prior year, and gross margin is very high, suggesting strong unit economics on a small revenue base. However, profitability is the key issue: operating losses are extremely large relative to sales in TTM, and net losses are substantial. The historical trend shows highly volatile revenue (steep declines in 2023–2024 followed by a TTM spike) and persistent operating losses across most years, which undermines earnings quality and visibility.

Balance Sheet

Leverage looks modest in the most recent periods, with low debt relative to equity in TTM (Trailing-Twelve-Months) and 2024, which provides balance-sheet flexibility. That said, returns on shareholder capital are weak, with negative return on equity in TTM driven by large losses. The company also showed material balance-sheet risk historically (very high debt relative to equity in 2023), indicating the capital structure has been unstable across time.

Cash Flow

Cash generation remains a major weakness: operating cash flow and free cash flow are negative in TTM (Trailing-Twelve-Months) and have been negative consistently over the full history provided. Free cash flow deterioration in TTM versus the prior year adds pressure, and the business is not yet funding itself from operations. While the relationship between free cash flow and net income is not signaling a cash/earnings mismatch, the core issue is simply ongoing cash burn.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	653.39K	136.64K	1.36M	10.25M	9.89M	17.12M
Gross Profit	562.66K	6.00K	49.03K	5.52M	4.75M	5.71M
EBITDA	-16.54M	-17.39M	-6.29M	-1.87M	-5.15M	-2.40M
Net Income	-20.55M	9.07M	-17.84M	-3.47M	-5.32M	-2.54M
Balance Sheet
Total Assets	104.83M	104.85M	12.53M	3.71M	5.77M	9.79M
Cash, Cash Equivalents and Short-Term Investments	355.69K	308.10K	314.00	1.09M	3.12M	5.92M
Total Debt	2.02M	3.53M	6.76M	1.58M	1.25M	627.46K
Total Liabilities	22.16M	25.78M	11.99M	3.37M	2.00M	1.11M
Stockholders Equity	82.67M	79.07M	542.35K	763.14K	3.77M	8.68M
Cash Flow
Free Cash Flow	-11.11M	-14.28M	-2.23M	-1.56M	-2.59M	-2.25M
Operating Cash Flow	-11.11M	-14.27M	-2.23M	-1.56M	-2.57M	-2.21M
Investing Cash Flow	0.00	27.55M	-275.72K	-427.85K	-22.60K	-37.51K
Financing Cash Flow	11.04M	-12.98M	1.41M	-35.17K	-208.18K	5.30M

Scienture Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNX, the sentiment is Positive. The current price of 0.55 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.49, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.11 is Neutral, neither overbought nor oversold. The STOCH value of 43.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCNX.

Scienture Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNX	45 Neutral	$15.62M	-0.23	-44.11%	―	-73.18%	92.38%
ZCMD	43 Neutral	$5.81M	-1.22	-8.96%	―	-24.64%	92.19%
HCTI	41 Neutral	$4.44M	―	-182.56%	―	-21.88%	68.40%
VSEE	38 Underperform	$14.50M	-0.45	―	―	187.24%	82.90%

Scienture Holdings Corporate Events

Scienture Holdings Updates Investor Presentation Strategy

On November 17, 2025, Scienture Holdings, Inc. released a revised investor presentation on its website, aimed at engaging analysts, potential investors, and other stakeholders. The presentation, which is part of the company’s ongoing communication strategy, includes forward-looking statements about its projects, potential financial performance, and growth opportunities, highlighting the inherent risks and uncertainties that could impact future results.

The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.

Scienture Holdings’ Stockholders Approve Key Proposals

On November 12, 2025, Scienture Holdings, Inc. held its 2025 Annual Meeting of Stockholders virtually, where stockholders voted on six key proposals. The stockholders elected five directors to the board and approved amendments to the 2019 Equity Incentive Plan and a potential future offering of common stock. However, they rejected the proposal to increase the number of authorized shares of common and preferred stock. Additionally, the stockholders approved granting the board discretion to implement a reverse stock split and the option to adjourn the meeting if necessary, although the latter was deemed unnecessary due to sufficient votes.

The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.

Scienture Holdings Expands Equity Distribution Agreement

On November 7, 2025, Scienture Holdings, Inc. filed a prospectus supplement with the SEC to increase the amount of common stock it can sell under an equity distribution agreement with Maxim Group LLC to $150 million. This move allows the company to potentially raise significant capital, impacting its financial strategy and market operations.

The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.